TY - JOUR T1 - Topotecan-induced Alterations in the Amount and Stability of Human DNA Topoisomerase I in Solid Tumor Cell Lines JF - Anticancer Research JO - Anticancer Res SP - 1745 LP - 1752 VL - 24 IS - 3A AU - JÉROME DEVY AU - RICHARD WARGNIER AU - MICHEL PLUOT AU - IGOR NABIEV AU - ALYONA SUKHANOVA Y1 - 2004/05/01 UR - http://ar.iiarjournals.org/content/24/3A/1745.abstract N2 - Background: Human DNA topoisomerase I (topo 1) is an essential nuclear enzyme involved in vital cellular processes and the sole target of antitumor drugs of the camptothecin (CPT) family. The CPT derivative topotecan (Tpt, Hycamtin®) is currently used in clinic, its effectiveness varying considerably for different types of cancer. The purpose of this study was to compare time- and dose-dependent cellular responses to Tpt in terms of alterations in the amount and stability of topo 1 in lung adenocarcinoma (A-549), ovarian adenocarcinoma (CaOv-3), colorectal adenocarcinoma (HT-29) and breast adenocarcinoma (MCF-7) cell lines. Materials and Methods: Western blot analysis of the time-dependent redistribution of a full-size topo 1 and its proteolytical fragments was performed after Tpt treatment for 1 h at concentrations 10-fold or 100-fold higher than the Tpt IC50 for the respective cell lines. Results: Tpt treatment of the CaOv-3 cell line produced a substantial time-dependent decrease in the amount of topo 1 immunoprotein. Conversely, the MCF7 cell line did not exhibit a topo 1-associated response to the Tpt treatment. Strong but different time- and dose-dependent topo 1 down-regulation effects were observed in the HT-29 and A-549 cell lines. Conclusion: The data obtained indicate that Tpt-induced time-and dose-dependent effects on the amount and stability of topo 1 are involved in the mechanisms of Tpt activity against different solid tumor cell lines. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -